Username or E-mail:

Password:

EULA

Forgot Password

Username:

E-mail:

Password:

EULA

Forgot Password

Already a Member

Username or E-mail

Send Forgot Mail

Back to Login

EULA

İrtibat

Logout

ZVSA

Closed

Zyversa Therapeutics Inc.

0.61

+0.05 (+8.88%)

Last Update: 24 Apr 2024 23:01:00

Yesterday: 0.563

Day's Range: 0.5736 - 0.6199

Send

inforMate

When Written:

1.69

ZyVersa Therapeutics Inc. is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for patients with inflammatory and renal diseases. The company's focus is on developing proprietary drugs that target the underlying causes of these diseases, with a goal of improving patient outcomes and quality of life.

ZyVersa's lead product candidate, VAR 200, is a novel, orally administered small molecule inhibitor of the inflammasome complex. It is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with moderate to severe atopic dermatitis.

The company also has a pipeline of other product candidates, including VAR 300, a potential treatment for diabetic nephropathy, and VAR 400, a potential treatment for lupus nephritis.

ZyVersa was founded in 2015 and is headquartered in Westlake Village, California. The company is led by a team of experienced executives and scientists with a proven track record of developing successful therapies for inflammatory and renal diseases.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.

(0)

Send

inforMate

When Written:

1.69

ZyVersa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for inflammatory and renal diseases. The company's lead product candidate, VAR 200, is a novel, orally-administered, small molecule inhibitor of pro-inflammatory cytokines that is being developed for the treatment of various inflammatory diseases, including psoriasis, rheumatoid arthritis, and lupus. ZyVersa also has a pipeline of other product candidates, including ZYP-101, which is being developed for the treatment of focal segmental glomerulosclerosis (FSGS) and other renal diseases. The company is headquartered in Westlake Village, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.

(0)

Send

Contact with us

Mail:

Message:

Cancel

Send

IP Adresiniz:18.191.21.86

YASAL UYARI:

   Finansal veriler Unicorn Data Services A.Ş. tarafından sağlanmaktadır. Hisse senedi verileri 15 dakika gecikmeli, Tahvil-Bono-Repo özet verileri de 15 dakika gecikmelidir. Burada sunulan yatırım bilgi, yorum ve tavsiyeler kesinlikle yatırım danışmanlığı hizmeti kapsamında değildir. Yatırım danışmanlığı hizmeti; aracı kurumlar, portföy yönetim şirketleri ve mevduat kabul etmeyen bankalarla müşteri arasında imzalanan yatırım danışmanlığı sözleşmesi çerçevesinde sunulmaktadır. Burada yer alan yorum ve tavsiyeler, ilgili kişilerin kişisel görüşlerine dayanmaktadır. Bu görüşler, mali durumunuz ve risk/getiri tercihlerinizle uygun olmayabilir.

   Bu nedenle, yalnızca burada yer alan bilgilere dayanarak yatırım kararı verirken beklentilerinize uygun sonuçlar elde edemeyebilirsiniz. Web sitemizde veya kullanılan kaynaklarda olabilecek hata ve eksikliklerden, bilgilerin kullanımından doğrudan veya dolaylı olarak kaynaklanabilecek yatırımcıların zararlarından, kar kayıplarından, manevi zararlardan ve üçüncü kişilerin uğrayabileceği zararlardan dolayı Noktacom Medya İnternet Hizmetleri San. ve Tic. A.Ş. hiçbir şekilde sorumlu tutulamaz.

   BİST (Borsa İstanbul) isim ve logosu "Koruma Marka Belgesi" altında korunmakta olup, izinsiz kullanılamaz, kopyalanamaz ve değiştirilemez. BİST adı altında açıklanan tüm bilgilerin telif hakları tamamen BİST'e aittir ve tekrar yayınlanması kesinlikle yasaktır.

PRICE DISCLAIMER:

   The information provided on our website [https://www.fiyaat.com] (the "Site") regarding stock market prices and foreign exchange rates is for general informational purposes only. While we strive to provide accurate and up-to-date information, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained on the Site.

   Any reliance you place on such information is strictly at your own risk. We strongly advise you to conduct your own research and seek professional advice before making any investment or trading decisions based on the information provided on our Site.

   We do not guarantee the accuracy, timeliness, performance, completeness, or suitability of the information and materials found or offered on the Site for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors, and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

   In no event will we be liable for any loss or damage including, without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of or in connection with the use of the Site.

   Through the Site, you may be able to link to other websites that are not under our control. We have no control over the nature, content, and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorsement of the views expressed within them.

   Every effort is made to keep the Site up and running smoothly. However, we take no responsibility for, and will not be liable for, the Site being temporarily unavailable due to technical issues beyond our control.